Blocking BCL-XL Increases ADC Effectiveness

UCLA researchers have reported a promising way to improve antibody-drug conjugates, or ADCs, in metastatic castration-resistant prostate cancer, a disease that remains difficult to control once it stops responding to hormone therapy. Their work suggests that pairing ADCs with a drug that blocks BCL-XL can make prostate cancer cells more vulnerable, leading to greater cell death and slower tumor growth in preclinical models.

Antibody-drug conjugates are designed to act like guided missiles: an antibody recognizes a target on cancer cells, and the linked drug payload is delivered directly into the tumor. That strategy has already changed treatment in several cancers, but in prostate cancer the benefits have so far been modest and often short-lived.

The UCLA team looked for a way to strengthen the approach rather than inventing a completely new therapy. They first analyzed tumor samples from patients with advanced prostate cancer and found that three proteins often used as ADC targets, B7-H3, PSMA, and STEAP1, can appear on the same cancer cells. That matters because it raises the possibility of targeting the same tumor through more than one surface protein at once.

They then tested many combinations of payload drugs and found a standout pairing: DNA-damaging agents plus a BCL-XL inhibitor. The logic is straightforward. DNA-damaging drugs push cancer cells toward death, while BCL-XL normally helps those cells survive by blocking programmed cell death. When BCL-XL is inhibited, the tumor loses a key escape route and becomes much less able to recover from the damage.

In lab-grown prostate cancer cells, the combination caused substantially more cell death than either treatment alone. In mice with advanced prostate tumors, it also slowed tumor growth more effectively than either therapy by itself. The researchers additionally observed that tumors with intact TP53 seemed to respond especially well, hinting that genetic testing could someday help identify patients most likely to benefit.

This study is important because it points to a practical path forward for a class of therapies that already exists. Instead of starting from scratch, the researchers are trying to make ADCs work better by matching the right targets with the right payload chemistry. If future clinical trials confirm these results, the approach could help move ADCs closer to a more durable role in advanced prostate cancer treatment.

Source.